共 50 条
- [21] A phase 2 trial of lenvatinib in combination with everolimus in patients with advanced or metastatic non-clear cell renal cell carcinomaBJU INTERNATIONAL, 2016, 118 : 14 - 15Hutson, ThomasXing, DongyuanDutcus, CorinaBaig, MahadiFishman, Mayer
- [22] Efficacy of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma: a systematic reviewANNALS OF ONCOLOGY, 2024, 35 : S1400 - S1400Budianto, C. J.Sabran, M. Z.Hutauruk, C. E. O. L.Purushotama, N. B. S. A.Kurniawan, A.Huang, I.
- [23] Lenvatinib plus pembrolizumab combination therapy for adult patients with advanced renal cell carcinomaEXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (10) : 1049 - 1059Ged, YasserLee, Chung-Han
- [24] A pilot study of thalidomide in patients with progressive metastatic renal cell carcinomaCANCER, 2002, 95 (04) : 758 - 765Daliani, DDPapandreou, CNThall, PFWang, XMPerez, COliva, RPagliaro, LAmato, R
- [25] Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular CarcinomaJOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (26) : 2960 - +Finn, Richard S.Ikeda, MasafumiZhu, Andrew X.Sung, Max W.Baron, Ari D.Kudo, MasatoshiOkusaka, TakujiKobayashi, MasahiroKumada, HiromitsuKaneko, ShuichiPracht, MarcMamontov, KonstantinMeyer, TimKubota, TomokiDutcus, Corina E.Saito, KenichiSiegel, Abby B.Dubrovsky, LeonidMody, KalgiLlovet, Josep M.
- [26] Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 studyLANCET ONCOLOGY, 2021, 22 (07): : 946 - 958Lee, Chung-HanShah, Amishi YogeshRasco, DrewRao, ArpitTaylor, H. MatthewDi Simone, ChristopherHsieh, J. JamesPinto, AlvaroShaffer, R. DavidSarrio, Regina GironesCohn, Allen LeeVogelzang, J. NicholasBilen, Mehmet AsimRibe, Sara GunnestadGoksel, MusaberkTennoe, Oyvind KrohnRichards, DonaldSweis, F. RandyCourtright, JayHeinrich, DanielJain, SharadWu, JaneSchmidt, V. EmmettPerini, F. RodolfoKubiak, PeterOkpara, E. ChinyereSmith, D. AlanMotzer, J. Robert
- [27] Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib armsFRONTIERS IN ONCOLOGY, 2023, 13Grunwald, ViktorPowles, ThomasEto, MasatoshiKopyltsov, EvgenyRha, Sun YoungPorta, CamilloMotzer, RobertHutson, Thomas E.Mendez-Vidal, Maria JoseHong, Sung-HooWinquist, EricGoh, Jeffrey C.Maroto, PabloBuchler, TomasTakagi, ToshioBurgents, Joseph E.Perini, RodolfoHe, CixinOkpara, Chinyere E.McKenzie, JodiChoueiri, Toni K.
- [28] Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib armsONKOUROLOGIYA, 2024, 20 (01): : 24 - 35Gruenwald, V.Powles, T.Eto, M.Kopyltsov, E.Rha, S. Y.Porta, C.Motzer, R.Hutson, T. E.Mendez-Vidal, M. J.Hong, S. H.Winquist, E.Goh, J. C.Maroto, P.Buchler, T.Takagi, T.Burgents, J. E.Perini, R.He, C.Okpara, C. E.McKenzie, J.Choueiri, T. K.
- [29] Pembrolizumab for previously treated metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: Phase 2 KEYNOTE-180 study.JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)Shah, Manish A.Bennouna, JaafarShen, LinEnzinger, Peter C.Li, QiaoCsiki, IldikoKoshiji, MinoriDoi, Toshihiko
- [30] Treatment outcome for metastatic papillary renal cell carcinoma patientsCANCER, 2006, 107 (11) : 2617 - 2621Rormen, Ellen A.Kondagunta, G. VaruniIshill, NicoleSpodek, LesleyRusso, PaulReuter, VictorBacik, JenniferMotzer, Robert J.